Industry News

• Pulmatrix receives IND approval for pulmazole phase 2 clinical study Pulmatrix announced the FDA completed its IND review and notified the Company that it is authorized to initiate a Phase 2 clinical investigation for Pulmazole (PUR1900) – an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for treatment of ABPA in patients with asthma.
  February 07, 2019

More...